Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
7.68
-0.32 (-4.00%)
At close: Dec 5, 2025, 4:00 PM EST
7.76
+0.08 (1.04%)
After-hours: Dec 5, 2025, 6:28 PM EST
Relay Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Relay Therapeutics stock have an average target of 16, with a low estimate of 6.00 and a high estimate of 23. The average target predicts an increase of 108.33% from the current stock price of 7.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Relay Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 8 | 8 | 6 |
| Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 13 | 13 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $4 → $6 | Hold | Maintains | $4 → $6 | -21.87% | Nov 7, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +95.31% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 → $14 | Strong Buy | Maintains | $16 → $14 | +82.29% | Aug 26, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $29 → $19 | Strong Buy | Maintains | $29 → $19 | +147.40% | Aug 8, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $30 → $10 | Strong Buy | Maintains | $30 → $10 | +30.21% | May 7, 2025 |
Financial Forecast
Revenue This Year
12.06M
from 10.01M
Increased by 20.47%
Revenue Next Year
8.08M
from 12.06M
Decreased by -32.94%
EPS This Year
-1.77
from -2.36
EPS Next Year
-1.69
from -1.77
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 40.3M | 42.2M | ||||
| Avg | 12.1M | 8.1M | ||||
| Low | 7.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 302.9% | 250.1% | ||||
| Avg | 20.5% | -32.9% | ||||
| Low | -21.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.58 | -1.41 | ||||
| Avg | -1.77 | -1.69 | ||||
| Low | -2.04 | -2.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.